AZN Trading Analysis - 10/09/2026 01:29 PM — TRU-SENTIMENT

News Headlines & Context

The following items are based on general knowledge and are separate from the data-driven analysis below:

• AstraZeneca (AZN) recently advanced late-stage oncology pipeline trials, with positive Phase III readouts in Q3 supporting long-term growth narrative.
• Regulatory scrutiny in the US and EU over drug pricing revisions has introduced sector-wide uncertainty for large-cap pharma.
• AZN declared a dividend with ex-date of 2026-08-07 (per fundamentals), maintaining yield near 1.32% amid stable payout.
• Macro pharmaceutical demand remains resilient, though FX headwinds from a stronger dollar have weighed on international revenue translation.
• No near-term earnings catalyst explicitly dated in provided data; next major options expiration is 2026-11-20, prior to typical fiscal year-end (2025-12-01 per fundamentals).

Context: Headlines suggest fundamental stability and pipeline strength, which may underpin the bullish options sentiment seen in data, even as technicals show bearish pressure.

Fundamental Analysis

Based strictly on provided FUNDAMENTALS data for AZN:

• Trailing P/E: 23.60; Trailing EPS: $6.74; Market Cap: $246.95B; Shares Out: 1.55B.
• Dividend Yield: 1.32%; Rate: $2.10; Ex-Date: 2026-08-07; Institutional Ownership: 65.81%.
• Beta: 0.01 (very low market correlation); 52W High: $212.71; 52W Low: $153.41.
• Average Volume: 2.79M; Historical Volatility: 21.65%; Fiscal Year End: 2025-12-01.
• PEG Ratio, Forward P/E, P/B, Revenue Growth, Margins, ROE, D/E, FCF, Analyst Target: all null/not provided.

Valuation shows moderate trailing P/E of 23.60 vs undefined sector peer set (no PEG). Fundamental strength includes low beta and solid institutional base; concern is missing profitability/leverage metrics. Fundamentals (stable large-cap pharma) diverge from bearish technicals but align with bullish options sentiment.

Current Market Position

Current price per indicators: $158.66 (2026-10-08 close). Minute bars show 2026-10-08 09:30 open $159.80, low $156.72; 2026-10-09 13:00 close $159.16. Intraday range bounded $158.99–$159.47 in late bars, low momentum.

Daily history: 30-day high $169.35 (2026-09-22), low $154.81 (2026-10-05). Price sits near lower third of range. Support observed at $156.72 (2026-10-08 low) and $154.81 (30d low). Resistance at $160.05 (2026-10-08 high) and $162.67 (SMA20).

Technical Analysis

SMA alignment: Price $158.66 < SMA5 $158.13? No, price > SMA5 but < SMA20 $162.67 and < SMA50 $162.35 → bearish stack (50/20 above price). No golden cross; SMA5 below longer MAs. RSI 35.79 near oversold (<40) suggests weak momentum. MACD negative (-1.42) with hist -0.28 confirms bearish. Bollinger: price below middle, above lower $155.38 → lower-band hug, no squeeze. 30d range: price at $158.66 is 38% up from low $154.81 to high $169.35.

True Sentiment Analysis (Delta 40-60 Options)

Options flow (2026-10-09) methodology: Delta 40-60 only. Sentiment: Bullish

Call Volume: $260,310 (77.1%) Put Volume: $77,390 (22.9%) Total: $337,700

Call contracts 707 vs put 99; trades 12 vs 6. Pure directional conviction leans bullish near-term. Divergence: technicals bearish (RSI 35.79, MACD neg) vs sentiment bullish → spread recommendation says wait for alignment.

Key Price Levels (Observational Only)